Destiny Pharma PLC Director/PDMR Shareholding (8614A)
May 26 2023 - 9:27AM
UK Regulatory
TIDMDEST
RNS Number : 8614A
Destiny Pharma PLC
26 May 2023
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Director/PDMR Shareholding
Brighton, United Kingdom - 26 May 2023 - Destiny Pharma plc
(AIM: DEST), a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent
life-threatening infections, announces that it was notified on 26
May 2023 that on that same day, Nick Rodgers, Chairman of the
Company, purchased 20,000 ordinary shares of 1 pence each in the
Company ("Ordinary Shares") at a price of 30.19 pence.
Following the purchase, Mr. Rodgers' beneficial interest in the
Company is 238,901 Ordinary Shares, representing 0.25 per cent. of
the total issued share capital.
For further information, please contact:
Destiny Pharma plc
Dr Debra Barker, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate
Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has completed a positive Phase 2 clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections
including MRSA. It is also co-developing SPOR-COVTM, a novel,
biotherapeutic product for the prevention of COVID-19 and other
viral respiratory infections and has earlier grant funded XF drug
research projects.
For further information on the Company, please visit
https://www.destinypharma.com
Further information is disclosed below pursuant to Article 19(3)
of the Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Nick Rodgers
------------------------------- -----------------------------------
2. Reason for the Notification
--------------------------------------------------------------------
a) Position/status Chairman
------------------------------- -----------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------- -----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- -----------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------
a) Description of the Ordinary shares of 1 pence each in
Financial instrument, Destiny Pharma Plc
type of instrument
------------------------------- -----------------------------------
Identification code GB00BDHSP575
------------------------------- -----------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
30.1898 pence 20,000
----------
------------------------------- -----------------------------------
d) Aggregated information:
* Aggregated volume See 4c) above
* Price
------------------------------- -----------------------------------
e) Date of the transaction 26 May 2023
------------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
------------------------------- -----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFFSERIRFIV
(END) Dow Jones Newswires
May 26, 2023 10:27 ET (14:27 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024